ProBioGen AG has announced signing a contract with Virdante Biopharmaceuticals, Inc., a US-based biopharmaceutical development company.
ProBioGen will contribute producer cell line development and process engineering for one of Virdante’s proprietary therapeutic proteins. Virdante’s protein products are unique in that they incorporate the company’s proprietary “Sialic Switch” technology that improves the anti-inflammatory properties of an antibody for autoimmune and inflammatory diseases. Virdante selected ProBioGen for its expertise in developing royalty-free pharmaceutical cell lines and robust, economical processes for GMP-manufacturing.
“We are highly impressed by Virdante´s products and strategies and their compelling scientific rationale to improve human proteins. We are excited to contribute our knowledge in harnessing the cellular machinery to maximize productivity for this ambitious project“, commented Dr. Volker Sandig, Chief Scientific Officer of ProBioGen.
ProBioGen Signs Therapeutic Protein Process Development Contract with Virdante Pharmaceuticals
News Apr 28, 2010
Read Time:
RELATED ARTICLES
News
Once simply thought to be microscopic sacks of cellular “garbage”, exosomes are now understood to hold immense importance for our health. In a new study, researchers show that exosomes are not only integral to the development of neurons and neural circuits, but they can restore health to brain cells affected by developmental disease.
READ MORE
Like what you just read? You can find similar content on the communities below.
Proteomics & MetabolomicsTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
